ATE69168T1 - Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung. - Google Patents

Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung.

Info

Publication number
ATE69168T1
ATE69168T1 AT87310141T AT87310141T ATE69168T1 AT E69168 T1 ATE69168 T1 AT E69168T1 AT 87310141 T AT87310141 T AT 87310141T AT 87310141 T AT87310141 T AT 87310141T AT E69168 T1 ATE69168 T1 AT E69168T1
Authority
AT
Austria
Prior art keywords
dioxacycloalkanes
carbon atoms
percutaneous absorption
therapeutic agents
preferred compounds
Prior art date
Application number
AT87310141T
Other languages
English (en)
Inventor
Carlos M Samour
Stefanos Daskalakis
Original Assignee
Macrochem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corp filed Critical Macrochem Corp
Application granted granted Critical
Publication of ATE69168T1 publication Critical patent/ATE69168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/16—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT87310141T 1986-11-17 1987-11-17 Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung. ATE69168T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/931,653 US4861764A (en) 1986-11-17 1986-11-17 Percutaneous absorption enhancers, compositions containing same and method of use
EP87310141A EP0268460B1 (de) 1986-11-17 1987-11-17 Mittel zur Verbesserung der perkutanen Absorption, diese enthaltende Arzneimittel und Methode zu ihrer Verwendung

Publications (1)

Publication Number Publication Date
ATE69168T1 true ATE69168T1 (de) 1991-11-15

Family

ID=25461144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87310141T ATE69168T1 (de) 1986-11-17 1987-11-17 Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung.

Country Status (7)

Country Link
US (1) US4861764A (de)
EP (1) EP0268460B1 (de)
AT (1) ATE69168T1 (de)
CA (1) CA1313619C (de)
DE (1) DE3774398D1 (de)
ES (1) ES2038676T3 (de)
GR (1) GR3003238T3 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576605A4 (en) * 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
EP0552879B1 (de) * 1992-01-21 1998-08-19 Macrochem Corporation Iontophoretische verbesserte Verabreichung von Medikamenten
EP0656356A1 (de) * 1992-08-21 1995-06-07 Japan Tobacco Inc. Dioxacycloalkanverbindung mit reninhemmender wirkung
US5334615A (en) * 1992-12-17 1994-08-02 Walles Wilhelm E Oil with bactericidal and virucidal properties
US5637616A (en) * 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
US5620980A (en) 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
TW420673B (en) * 1996-09-10 2001-02-01 Daiso Co Ltd Process for preparing 1,3-dioxolane-4-methanol compound
EP0926147B1 (de) * 1996-09-10 2003-08-27 Daiso Co., Ltd. Verfahren zur herstellung von 1,3-dioxolan-4-methanol-verbindungen
DE19711758C2 (de) * 1997-03-21 2003-06-18 Degussa Verfahren zur Herstellung von 1,3-Dioxanverbindungen
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6153769A (en) * 1997-11-27 2000-11-28 Roche Vitamins Inc. Manufacture of polyene aldehydes
CA2278328C (en) * 1998-02-09 2008-07-22 Macrochem Corporation Antifungal nail lacquer and method using same
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
PL346238A1 (en) * 1998-08-20 2002-01-28 3M Innovative Properties Co Spray on bandage and drug delivery system
US7537773B1 (en) * 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6596266B2 (en) 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
US7241731B2 (en) 2000-06-05 2007-07-10 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
US20050008602A1 (en) * 2000-06-05 2005-01-13 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
CA2466425A1 (en) * 2001-11-09 2003-05-15 Qlt Inc. Photodynamic therapy for the treatment of hair loss
IL163981A0 (en) * 2002-03-15 2005-12-18 Unimed Pharmaceuticals Inc Androgen pharmaceutical composition and method fortreating depression
EP1635770B1 (de) 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antimykotischer nagellack und anwendungsverfahren
EP1605948A1 (de) * 2003-03-21 2005-12-21 Nexmed Holdings, Inc. Prostaglandin- zusammensetzungen zur behandlung von erektionsstörungen
DE10314976A1 (de) * 2003-04-02 2004-10-14 Bayer Healthcare Ag Verbesserte Penetration von Wirkstoffen in Zellen und Organe
KR20050041815A (ko) * 2003-10-31 2005-05-04 싸이토팜(주) 자외선에 의한 피부손상을 경감시키는 항산화 조성물
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
FR2869232B1 (fr) * 2004-04-21 2007-09-21 Gattefosse Sas Soc Par Actions Nouveaux excipients pharmaceutiques ou cosmetiques a base d'acetals cyliques
KR20070121746A (ko) * 2005-03-14 2007-12-27 매크로켐 코포레이션 사람 피부를 통한 마크롤라이드 침투의 개선
MX2007013912A (es) * 2005-05-11 2008-03-25 Macrochem Corp Administracion de baja dosis de una composicion topica.
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
GT200600397A (es) * 2005-09-07 2007-08-28 Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
CA2999420A1 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
WO2007051243A1 (en) 2005-11-04 2007-05-10 Acrux Dds Pty Ltd Method and system for transdermal drug delivery
EP2244690B1 (de) 2007-10-10 2017-08-02 Therametics, Llc Topische Zusammensetzungen zur Behandlungen von entzündlichen Erkrankungen und Leiden
EP2579847A1 (de) 2010-06-11 2013-04-17 Pola Pharma Inc. Antimykotische pharmazeutische zusammensetzung
EP2717888B1 (de) 2011-06-10 2020-09-09 Tissuetech, Inc. Verfahren zur verarbeitung fötaler gewebesubstrate
CA2844115C (en) 2011-08-26 2021-11-23 Tissuetech, Inc. Methods of sterilizing fetal support tissues
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
CA2968299A1 (en) 2014-11-18 2016-05-26 Rutgers, The State University Of New Jersey Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
US10227315B2 (en) 2016-05-18 2019-03-12 Rutgers, The State University Of New Jersey Mitochondrial uncouplers for treatment of metabolic diseases and cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1082370B (de) * 1958-01-18 1960-05-25 C F Asche & Co Ag Verfahren zur Herstellung von verformbaren Massen fuer kosmetische und pharmazeutische Zwecke
GB1385914A (en) * 1971-10-19 1975-03-05 Wigglesworth Ltd Compositions having bactericidal activity
US4012520A (en) * 1973-08-08 1977-03-15 The Upjohn Company Composition and method of producing infertility in male rodents
GB1448458A (en) * 1973-11-21 1976-09-08 Allen & Hanburys Ltd 1,3-dioxan derivatives and pharmaceutical compositions thereof
IT1037122B (it) * 1975-04-01 1979-11-10 Maggioni E C S P A Derivati alogenati dell 1 3 dios solano ad attivita mucolitica
EP0012543B1 (de) * 1978-11-30 1983-05-11 Imperial Chemical Industries Plc Zusammensetzungen, die 1,3 Dioxolane als Aufweichmittel enthalten
CA1225594A (en) * 1983-05-20 1987-08-18 Jourge Heller Method for percutaneously administering physiologically active agents
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one

Also Published As

Publication number Publication date
US4861764A (en) 1989-08-29
ES2038676T3 (es) 1993-08-01
DE3774398D1 (de) 1991-12-12
GR3003238T3 (en) 1993-02-17
EP0268460B1 (de) 1991-11-06
EP0268460A1 (de) 1988-05-25
CA1313619C (en) 1993-02-16

Similar Documents

Publication Publication Date Title
ATE69168T1 (de) Mittel zur verbesserung der perkutanen absorption, diese enthaltende arzneimittel und methode zu ihrer verwendung.
ATE154354T1 (de) Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE86247T1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
FI821598A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat
UA19808A (uk) Спосіб одержаhhя феhілалкіламіhів або солей цих сполук
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
FI811671L (fi) Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-foereningar med beta-receptor haemmande verkan
GR861803B (en) Novel carbonic acid derivatives method for their preparation their use and medicine containing them
GR3033528T3 (en) Novel piperidine derivatives with paf antagonist activity
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
DE3064835D1 (en) 2-hydroxyalkyl-3,4,5,trihydroxy piperidines, processes for their preparation and their use as medicaments
DE68917348D1 (de) Bor-dipeptid-Verbindungen, Methode zu deren Herstellung und pharmazeutische Anwendungen.
EP0431579A3 (en) Substituted cyclohexenes as central nervous system agents
DZ1407A1 (fr) Dérivés d-substitués des n,n'-ditriméthoxybenzoylepipérazine ainsi que leur procédé de préparation.
ATE43140T1 (de) Derivate von enzym-hemmender griseolsaeure und deren verwendung.
DE3665861D1 (en) Basically substituted phenylacetaldehydes, their preparation and therapeutic compositions containing them
ATE229953T1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
IT1223395B (it) Composti ad attivita' cardiovascolare
DE3483735D1 (en) Hexahydropyrrolo(2,1-a)isochinolinderivate.
ATE112256T1 (de) 9-amino-2-phenylbicyclo(3.3.1>nonane und 9-amino- 2-phenylbicyclo(3.3.1>-non-2-ene und diese enthaltende therapeutische mittel.
DE3862426D1 (de) 2-selenomethyl-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time